Sonoclot Analyzer and Platelet Aggregometry | Platelet Aggregation Analyzer | PFA

Sonoclot Analyzer and Platelet Aggregometry Detect Platelet Receptor (GPIIb/IIIa) Blockade

Yue Dong, M.D.; Gregory A. Nuttall, M.D.; William C. Oliver, M.D.; Mark H. Ereth, M.D. Anesthesiology, Mayo Clinic, Rochester, Minnesota, United States

[Background] Abciximab blocks the major platelet surface receptor (GPIIb/IIIa), which is critical to platelet aggregation. Practical means to monitor platelet function in patients on abciximab undergoing emergency cardiac surgery is needed. [Methods] After Institutional Review Board approval and informed consent, blood samples were drawn from 20 healthy volunteers. Celite activated Sonoclot analysis and ADP activated Platelet Poor Plasma (PRP) aggregometry were completed after addition of abciximab. The Sonoclot analysis and ADP activated PRP aggregometry were used to detect platelet function. The data was analyzed by student's t test and P<0.05 is statistically significant. [Result]ACT=Activated Clotting Time, PF=Sonoclot calculated platelet function [Discussion] Sonoclot analysis Time to Peak and PF values accurately reflect GPIIb/IIIa receptor blockade. Unlike platelet aggregometry which is the time consuming and labor intensive, the Sonoclot analyzer is a user friendly point of care test, which yields good results. Thus, Sonoclot analyzer provides rapid assessment of platelet function that could allow for adjustment of abciximab therapy or to direct platelet transfusion in the setting of cardiac surgery. Anesthesiology 2001; 95:A192

Control Abciximab Abciximab P-value 0.125mg/kg 0.25mg/kg Sonoclot ACT ( sec) 167±38 155±21 159±30 NS Clot Rate ( unit/min) 14.9±3.9 15.7±5.5 14.2±3.9 NS Time to Peak(min) 11.0±3.1* 13.0±3.5 18.1±5.2* *<0.05 PF 2.5±1.3* - 1.3±0.9* *<0.05 Aggregometry % Aggregation 85.2±6.1* 19.2±11.3* 9.4±4.2* *<0.05 n 20 10 20

For More information please visit: www.lifediagnostica.com